Predictors of Clinical Efficacy of Cytokine Hemoadsorption in COVID-19 (Clinical Trial)

Materials and methods. This study analyzed the results of treatment of 62 patients with severe COVID-19 in the intensive care unit using selective hemoadsorption of cytokines. All patients with severe COVID-19 were admitted to the intensive care unit within 14 days from the disease onset were subdivided into two groups. Group 1 patients (n=32) received on a top of standard treatment the hemoperfusion (HP) procedure for 4 hours, for 2–3 days in a row, using a cytokine sorption column composed of mesoporous styrene-divinilbenzen copolymer matrix. Group 2 patients were not subjected to extracorporeal blood purification. All patients received IL-6 inhibitors at a baseline in accordance to the temporary guidelines. We evaluated factors of unfavorable outcomes by analyzing changes in biochemical markers of systemic inflammatory response and mortality rates in patients of both groups.

Results. Initiation of HP later than 10 days from NCI onset (P < 0.001), length of stay in the ICU, extent of lung damage (P = 0.036) and the SOFA (Sequential Organ Failure Assessment) score (P = 0.009) were the most powerful predictors of unfavorable outcome. Levels of systemic inflammatory response markers (interleukin- 6, CRP, D-dimer) in both groups did not significantly affect the survival rates and length of hospital stay (P > 0.05). HP group demonstrated better survival (P < 0.05). Mean hospital stay was 31 and 27 days, ICU stay — 11 and 8 days for Groups 1 and 2, respectively (P < 0.05).

Conclusion. Treatment of severe COVID-19 patients with HP using novel domestic hemosorbent composed of styrene-divinilbenzen copolymer matrix resulted in decrease in CRP levels on the first day after application and, with early onset, contributed to a significant increase in survival and decreased hospital and ICU stay. Additional studies are warranted to clarify the optimal timing of the initiation of HP in severe COVID-19 patients.

1. Ochkin S.S., Samoylov A.S., Udalov Yu.D., Kruglyakov N.M., Bagzhanov G.I. Efficiency and safety of plasma exchange in the treatment of severe COVID-19. Anesthesiol. Reanimatol / Anesteziologiya i Yaroustovsky M.B., Shukevich D.L., Ushakova N.D., Sokolov A.A., Rey S.I. Blood purification methods in complex treatment of patients with a new coronavirus infection. Anesthesiol.Reanimatol/ Anesteziologiya i Reanimatologiya. 2020; (5): 47–55. (In Russ.).Reanimatologiya. 2021; (4): 48–53. (In Russ.).

2. Temporary guidelines for the treatment of coronavirus infection of the Ministry of Health of the Russian Federation. Version 13, dated 14.10.2021.

3. Polushin Yu.S., Аkmalova R.V., Sokolov D.V., Bovkun I.V., Gavrilova E.G., Shlyk I.V., Parshin E.V., Lapin S.V., Tkachenko O.Yu. Changes in the levels of some cytokines when using blood purification in COVID-19 patients. Messenger of Anesthesiology and Resuscitation/Vestnik Anesthesiologii i Reanimatologii. 2021; 18 (2): 31–39. (In Russ.).

4. Sokolov A.A., Sokolov D.V., Pevzner D.V., Popov A.V., Donskikh V.V. Extracorporeal blood purification in the complex treatment of the novel coronavirus infection: the review of opportunities. Messenger of Anesthesiology and Resuscitation/Vestnik Anesthesiologii i Reanimatologii. 2020; 17 (4): 31–40. (In Russ.).

5. Nassiri A.A., Hakemi M.S., Miri M.M., Shahrami R., Koomleh A.A., Sabaghian T. Blood purification with CytoSorb in critically ill COVID-19 patients: a case series of 26 patients. Artif Organs. 2021; 45(11): 1338–1347. DOI: 10.1111/aor.14024. PMID: 34152629

6. Vardanjani A.E., Ronco C., Rafiei H., Golitaleb M., Pishvaei M.H., Mohammadi M. Early hemoperfusion for cytokine removal may contribute to prevention of intubation in patients infected with COVID-19. Blood Purif. 2021; 50 (2): 257–260. DOI: 10.1159/000509107. PMID: 32594085

7. Mikaeili H., Taghizadieh A., Nazemiyeh M., Rezaeifar P., Vahed S.Z., Safiri S., Ardalan M., Ansarin K. The early start of hemoperfusion decreases the mortality rate among severe COVID-19 patients: a preliminary study. Hemodial Int. 2022; 26 (2): 176–182. DOI: 10.1111/hdi.12982. PMID: 34907633

8. Surasit K., Srisawat N. The Efficacy of early additional hemoperfusion therapy for severe COVID-19 patients: a prospective cohort study. Blood Purif. 2022; 5(11): 879–888. DOI: 10.1159/000521713. PMID: 35139519

9. Ramírez-Guerrero G., Cifuentes V.T., Hernández R.B., Cortés F.V., Doll S.R., Alarcón R.O., Córdova C.L., Fernandez P.F., Coloma O.G. Early cytokine removal in critical COVID-19 patients with extracorporeal therapies (HA-380 plus high volume hemofiltration) may prevent progression of acute respiratory distress syndrome: case report. Blood Purif. 2021; 50 (4–5): 575–577. DOI: 10.1159/000512982. PMID: 33264786

10. Liu Y., Gao W. , Guo W., Guo Y., Shi M., Dong G., Ge Q., Zhu J., Lu J. Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patient with COVID-19. Yang Liu at al. J Thromb Thrombolysis. 2020; 50 (4); 825–832. DOI: 10.1007/s11239020-02174-9. PMID: 32761495

11. Görlinger K., Dirkmann D., Gandhi A., Simioni P. COVID-19associated coagulopathy and inflammatory response: what do we know already and what are the knowledge gaps? Anesth Analg. 2020; 131(5): 1324–1333. DOI: 10.1213/ANE.0000000000005147. PMID: 33079850

12. Kutepov D.E., Pasko V.G., Gavrilov S.V., Khashukoeva I.Kh. Experience in the use of extracorporeal methods of detoxification in patients with COVID-19. Kremlin Medicine. Clinical Bulletin

13. / Kremlevskaya meditcina. Klinicheskii vestnik. 2020; 3: 27–32 (In Russ.). DOI:10.26269/jttd-d019.

14. Hadid T., Kafri Z., Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021; 47: 100761. DOI: 10.1016/j.blre.2020.100761. PMID: 33067035

15. Rampino T., Gregorini M., Perotti L., Ferrari F., Pattonieri E.F., Grignano M.A., Valente M., Garrone A., Islam T., Libetta C., Sepe V., Albertini R., Bruno R., Belliato M. Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia. Blood Purif. 2021; 50 (4–5): 566–571. DOI: 10.1159/000511725. PMID: 33181508

16. Al Shareef K., Bakouri M. Cytokine blood filtration responses in COVID-19. Blood Purif. 2021; 50 (2): 141–149. DOI: 10.1159/000508278. PMID: 32464624.

17. Shadvar K., Tagizadiyeh A., Gamari A.A., Soleimanpour H., Mahmoodpoor A. Hemoperfusion as a potential treatment for critically ill COVID-19 patients with cytokine storm. Blood Purif. 2021; 50 (3): 405–407. DOI: 10.1159/000511391. PMID: 33171470.

18. Iannaccone G., Scacciavillani R., Del Buono M.G., Camilli M., Ronco C., Lavie C.J., Abbate A., Crea F., Massetti M., Aspromonte N. Weathering the cytokine storm in COVID-19: therapeutic implications. Cardiorenal Med. 2020; 10 (5): 277–287. DOI: 10.1159/000509483. PMID: 32599589

19. Koc S., Uysal H. Literature review of hemadsorption therapy in severe COVID-19 cases: a narrative review. Clin Lab. 2022; 68 (2). DOI: 10.7754/Clin.Lab.2021.210839. PMID: 35142202.

20. Stockmann H., Keller T., Büttner S., Jörres A., Kindgen-Milles D., Kunz J.V., Leebmann J., Spies C., Träger K., Treskatsch S., Uhrig A., Willam C., Enghard P., Slowinski T.; CytoResc Trial Investigators. CytoResc — «CytoSorb» Rescue for critically ill patients undergoing the COVID-19 cytokine storm: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020; 21 (1): 577. DOI: 10.1186/s13063020-04501-0. PMID: 32586396

21. Faqihi F., Alharthy A., Alodat M., Asad D., Aletreby W., Kutsogiannis D.J., Brindley P.G., Karakitsos D. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): a structured summary of a randomized controlled trial study protocol. Trials. 2020; 21(1): 506. DOI: 10.1186/s13063-020-04454-4. PMID: 32513290

22. Song P., Li W., Xie J., Hou Y., You C. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020; 509: 280–287. DOI: 10.1016/j.cca.2020.06.017. PMID: 32531256

23. Ye Q., Wang B., Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020; 80 (6): 607–613. DOI: 10.1016/j.jinf.2020.03.037. PMID: 32283152

24. Tufan A., Güler A.A., Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020; 50 (SI-1): 620–632. DOI: 10.3906/sag-2004-168. PMID: 32299202

25. Magomedov M.A., Kim T.G., Masolitin S.V., Yaralian A.V., Kalinin E.Yu., Pisarev V.M. Use of sorbent based on hypercrosslinked styrene-divinylbenzene copolymer with mmobilized LPS-selective ligand in hemoperfusion for treatment of patients with septic shock. General Reanimatology / Obshchaya Reanimatologiya. 2020; 16 (6): 31–53. (In Russ. & Engl.). DOI: 10.15360/1813-9779-2020-6-31-53.

26. МоMorozov A.S., Bessonov I.V., Nuzhdina A.V., Pisarev V.M. Sorbents for extracorporeal removal of toxic substances and molecules with adverse biological activity (Review). General Reanimatology / Obshchaya Reanimatologiya. 2016; 12 (6): 82–107. (in Russ.).